Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure
Leo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotech will ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.